MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.anai.2022.01.002

Медицинская библиотека · Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2022

Real-life experience with hazelnut oral immunotherapy.

Sabouraud Marie, Biermé Priscille, André-Gomez Sylvie-Anne, Villard-Truc Florence, Payot François, Corréard Anne-Karine, Garnier Lorna, Braun Camille

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Hazelnut oral immunotherapy (H-OIT), a promising alternative to hazelnut-free diet for patients with hazelnut allergy, has not been extensively studied.

OBJECTIVE

To investigate the effectiveness of H-OIT for children with hazelnut allergy.

METHODS

Retrospective medical record review of children treated by H-OIT in the University Hospital of Lyon (France) was reported. Clinical and laboratory data were collected, and the satisfaction of the children treated by H-OIT was evaluated using a questionnaire.

RESULTS

A total of 70 patients treated by H-OIT for an immunoglobulin E-mediated hazelnut allergy (94.3%) or an immunoglobulin E sensitization to hazelnut (5.7%) were included. Among these, 22.9% entered the maintenance phase at 1-year consultation and 60.0% entered the maintenance phase during the study period. At home, 57.1% of the patients experienced at least 1 adverse effect and 2.9% experienced severe systemic allergic reactions. Among the 212 oral food challenges conducted at hospital, 3.3% led to severe systemic reactions and epinephrine was used 4 times. A total of 21.4% of children discontinued treatment; aversion to hazelnut was the main reason. There were 42 children aged 8 years or more and their parents who answered the questionnaire. H-OIT was considered a strain for children but effective and was recommended to other children with allergy.

CONCLUSION

H-OIT seemed to be effective and well accepted by children. This is counterbalanced by a high rate of H-OIT discontinuation, mainly owing to aversion to hazelnut, and an important rate of adverse reactions, which are however mostly mild.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04841850.

Для цитирования: Sabouraud Marie, Biermé Priscille, André-Gomez Sylvie-Anne, Villard-Truc Florence, Payot François, Corréard Anne-Karine, Garnier Lorna, Braun Camille. Real-life experience with hazelnut oral immunotherapy.. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2022. DOI: 10.1016/j.anai.2022.01.002.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.